Literature DB >> 8726038

Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin.

P Brouqui1, S Badiaga, D Raoult.   

Abstract

Despite appropriate antibiotic treatment, Lyme disease patients may have relapses or may develop chronic manifestations. The intracellular location of Borrelia burgdorferi suggests that antibiotics that penetrate cells will have greater efficiency. Doxycycline or erythromycin was more effective than penicillin or ceftriaxone in killing B. burgdorferi when the organism was grown in the presence of eucaryotic cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726038      PMCID: PMC163368          DOI: 10.1128/AAC.40.6.1552

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Penetration of endothelial cell monolayers by Borrelia burgdorferi.

Authors:  L E Comstock; D D Thomas
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

2.  Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis.

Authors:  J Schmidli; T Hunziker; P Moesli; U B Schaad
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

3.  Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro.

Authors:  K Georgilis; M Peacocke; M S Klempner
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

4.  Localization of Borrelia burgdorferi in murine Lyme borreliosis by electron microscopy.

Authors:  A R Pachner; J Basta; E Delaney; D Hulinska
Journal:  Am J Trop Med Hyg       Date:  1995-02       Impact factor: 2.345

5.  Interaction of Lyme disease spirochetes with cultured eucaryotic cells.

Authors:  D D Thomas; L E Comstock
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

6.  Intracellular localization of Borrelia burgdorferi within human endothelial cells.

Authors:  Y Ma; A Sturrock; J J Weis
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

7.  Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; E Schielke; F Sörgel; K M Einhäupl
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

8.  Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin.

Authors:  R J Dattwyler; J J Halperin; D J Volkman; B J Luft
Journal:  Lancet       Date:  1988-05-28       Impact factor: 79.321

  8 in total
  6 in total

1.  NOD2 plays an important role in the inflammatory responses of microglia and astrocytes to bacterial CNS pathogens.

Authors:  Vinita S Chauhan; David G Sterka; Samantha R Furr; Amy B Young; Ian Marriott
Journal:  Glia       Date:  2009-03       Impact factor: 7.452

Review 2.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

3.  Invasion of eukaryotic cells by Borrelia burgdorferi requires β(1) integrins and Src kinase activity.

Authors:  Jing Wu; Eric H Weening; Jennifer B Faske; Magnus Höök; Jon T Skare
Journal:  Infect Immun       Date:  2010-12-20       Impact factor: 3.441

Review 4.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

5.  Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis.

Authors:  Ruben Magni; Benjamin H Espina; Ketul Shah; Benjamin Lepene; Christine Mayuga; Temple A Douglas; Virginia Espina; Sally Rucker; Ross Dunlap; Emanuel F Iii Petricoin; Mary Frekko Kilavos; Donald M Poretz; Gilbert R Irwin; Samuel M Shor; Lance A Liotta; Alessandra Luchini
Journal:  J Transl Med       Date:  2015-11-04       Impact factor: 5.531

6.  Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group.

Authors:  Samuel Shor; Christine Green; Beatrice Szantyr; Steven Phillips; Kenneth Liegner; Joseph Jr Burrascano; Robert Bransfield; Elizabeth L Maloney
Journal:  Antibiotics (Basel)       Date:  2019-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.